within Pharmacolibrary.Drugs.ATC.J;

model J05AF12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0002666666666666667,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AF12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Clevudine is a nucleoside analog antiviral drug primarily developed for the treatment of chronic hepatitis B virus (HBV) infection. It inhibits DNA synthesis of HBV by acting as a reverse transcriptase inhibitor. Clevudine is not currently approved for use in the United States or many other major markets, but was approved and used in certain Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult healthy volunteers and patients with chronic hepatitis B following oral administration.</p><h4>References</h4><ol><li><p>Squires, KE, et al., &amp; De La Rosa, A (2020). ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. <i>Antimicrobial agents and chemotherapy</i> 64(9) –. DOI:<a href=\"https://doi.org/10.1128/AAC.00836-20\">10.1128/AAC.00836-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32540975/\">https://pubmed.ncbi.nlm.nih.gov/32540975</a></p></li><li><p>Squires, KE, et al., &amp; Mayers, DL (2023). A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection. <i>Journal of viral hepatitis</i> 30(1) 19–28. DOI:<a href=\"https://doi.org/10.1111/jvh.13753\">10.1111/jvh.13753</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36201354/\">https://pubmed.ncbi.nlm.nih.gov/36201354</a></p></li><li><p>Witcher, JW, et al., &amp; Chu, CK (1997). Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucks. <i>Antimicrobial agents and chemotherapy</i> 41(10) 2184–2187. DOI:<a href=\"https://doi.org/10.1128/AAC.41.10.2184\">10.1128/AAC.41.10.2184</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9333045/\">https://pubmed.ncbi.nlm.nih.gov/9333045</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AF12;
